Advertisement

Topics

Medicago Company Profile

21:04 EST 18th December 2018 | BioPortfolio

Medicago is a clinical-stage biopharmaceutical company developing novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The Company is committed to providing highly effective and competitive vaccines and therapeutic proteins based on its proprietary Virus-Like Particles (VLPs) and manufacturing technologies. Medicago is a worldwide leader in the development of VLP vaccines using a transient expression system which produces recombinant vaccine antigens in plants. This technology has potential to offer more potent vaccines with speed and cost advantages over competitive technologies, enabling the development of a vaccine for testing in approximately one month after the identification and reception of genetic sequences from a pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic, and supply large volumes of vaccine antigens to the world market. Medicago also intends to expand development into other areas such as biosimilars and biodefense products where the benefits of our technologies can make a significant difference.

Medicago has reported positive results from its Phase II clinical trial with its avian flu H5 pandemic vaccine candidate. The vaccine was found to be safe, well tolerated and the results were among the most effective of the industry. Medicago also reported positive results from a U.S. Phase I human clinical trial with its seasonal influenza vaccine candidate. All vaccine doses were found to be safe, well tolerated and also induced a solid immune response that met the CHMP criteria, even with a single dose of 5 µg. Based on these results and subject to regulatory approval, Medicago intends to proceed with a U.S. Phase IIa trial for its seasonal quadrivalent vaccine with the recommended H1N1, H3N2 and two B influenza strains.

Medicago operates a 24,000-square-foot production facility located in the Technology Park in Quebec City, Canada. This facility includes a Biosafety level 2 greenhouse, an extraction and purification unit, and is cGMP compliant. Medicago is producing the preclinical and clinical lots required for the development of its influenza vaccines from its existing facility.

Medicago U.S.A., a wholly owned subsidiary of Medicago Inc., has completed the construction of its facility in Research Triangle Park (RTP), North Carolina. This Virus-Like-Particle plant-based vaccine facility includes a fully automated greenhouse and a state of the art extraction and purification unit. The 97,000-square-foot cGMP facility is targeted to produce 10 million doses of pandemic influenza vaccine per month. On an annual basis, the facility could have production capacity of 30 million doses of quadrivalent seasonal influenza vaccine or 120 million doses of pandemic influenza vaccine.

Location

1020, route de l'Église, bureau 600
Québec
Quebec
G1V 3V9
Canada

Contact

Phone: 418 658.9393
Fax: 418 658.6699
Email: info@medicago.com


News Articles [10 Associated News Articles listed on BioPortfolio]

Medicago beginnt offiziell mit dem Bau seines Standorts in der Estimauville Innovation Area

QUÉBEC CITY, September 19, 2018 /PRNewswire/ -- Medicago, ein kanadisches Biotechunternehmen, das weltweit führend in der Entwicklung und Produktion von pflanzlichen Impfstoffen ist, hat heute Read...

Medicago Inc Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 23042018] Prices from USD $350

Medicago Inc Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Medicago Inc Mergers Acquisitions MA, Partnerships Alliances and Investments report includes ...

Medicago Inc Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 28072018] Prices from USD $350

Medicago Inc Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Medicago Inc Mergers Acquisitions MA, Partnerships Alliances and Investments report includes ...

Medicago Inc Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 30032018] Prices from USD $350

Medicago Inc Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Medicago Inc Mergers Acquisitions MA, Partnerships Alliances and Investments report includes ...

Medicago Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 17092018] Prices from USD $250

SummaryMedicago Inc Medicago, a subsidiary of Mitsubishi Tanabe Pharma Corp is a clinicalstage biotechnology company that develops and produces vaccines and antibodies. The company concentrates on the...

Medicago Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 23042018] Prices from USD $250

SummaryMedicago Inc Medicago, a subsidiary of Mitsubishi Tanabe Pharma Corp is a clinicalstage biotechnology company that develops and produces vaccines and antibodies. The company concentrates on the...

Medicago Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 06122018] Prices from USD $250

SummaryMedicago Inc Medicago, a subsidiary of Mitsubishi Tanabe Pharma Corp is a clinicalstage biotechnology company that develops and produces vaccines and antibodies. The company concentrates on the...

Global and Asia Bioactive Protein Market Status and Future Forecast 20132023 [Report Updated: 20082018] Prices from USD $3000

SummaryKey Content of Chapters Including and can be customizedPart 1:Market Overview, Development, and Segment by Type, Application RegionPart 2:Global Market by company, Type, Application RegionPar...

Drugs and Medications [11 Associated Drugs and Medications listed on BioPortfolio]

Fast arthritis aid [Concept Laboratories, Inc.]

FAST ARTHRITIS AID Pain Relieving Gel

Painazin cp [Concept Laboratories, Inc.]

PAINAZIN-CP THERAPEUTIC PAIN RELIEVING SPRAY

Moisturizing glucosamine brand [Concept Laboratories]

MOISTURIZING GLUCOSAMINE BRAND PAIN RELIEF ROLL-ON GEL

Mark. [Avon Products, Inc.]

Fresh juice e [SKINFOOD CO., LTD.]

Drug Facts

PubMed Articles [38 Associated PubMed Articles listed on BioPortfolio]

A Unified Agrobacterium-Mediated Transformation Protocol for Alfalfa (Medicago sativa L.) and Medicago truncatula.

Simplification of transformation procedures greatly improves work efficiency. In this chapter, we introduce a unified Agrobacterium-mediated transformation protocol that is used for both alfalfa (Medi...

Quantitative proteomic analysis using iTRAQ to identify salt-responsive proteins during the germination stage of two Medicago species.

Salt stress is one of the primary abiotic stresses responsible for decreasing crop yields worldwide. Germinating seeds can be greatly influenced by saline conditions. In this study, the physiological ...

Neuroprotective effects of triterpenoid saponins from Medicago sativa L. against HO-induced oxidative stress in SH-SY5Y cells.

Medicago sativa L. is a forage legume plant widely distributed in all continents. Six new triterpenoid saponins, Medicagosides A-F (1-6) and five known ones (7-11) were isolated from M. sativa. Their ...

A SOC1-like gene MtSOC1a promotes flowering and primary stem elongation in Medicago.

Medicago flowering, like that of Arabidopsis, is promoted by vernalization and long days, but alternative mechanisms are predicted because Medicago lacks the key regulators CO and FLC. Three Medicago ...

Localization of calreticulin and calcium ions in mycorrhizal roots of Medicago truncatula in response to aluminum stress.

Aluminum (Al) toxicity limits growth and symbiotic interactions of plants. Calcium plays essential roles in abiotic stresses and legume-Rhizobium symbiosis, but the sites and mechanism of Ca mobilizat...

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Effect of Medicago Sativa on Oral Glucose Tolerance in Healthy Adults

Previous preclinical investigations have found that Medicago sativa promotes the decrease of glucose concentrations. To evaluate the acute effect of Medicago sativa administration on gluco...

Companies [2 Associated Companies listed on BioPortfolio]

Medicago

Medicago is a clinical-stage biopharmaceutical company developing novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The Company is committed to provi...

Medicago Inc.

More Information about "Medicago" on BioPortfolio

We have published hundreds of Medicago news stories on BioPortfolio along with dozens of Medicago Clinical Trials and PubMed Articles about Medicago for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Medicago Companies in our database. You can also find out about relevant Medicago Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...

Vaccine
A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one ...


Corporate Database Quicklinks



Searches Linking to this Company Record